临床免疫学是临床医学中发展迅速的一个重要分支学科，是免疫学的重要组成部分，主要涉及各种免疫性疾病的诊治及研究。

2015年，在北京大学临床免疫和基础免疫长期积累和发展的基础上，由北京大学人民医院栗占国教授牵头成立了北京大学临床免疫中心，有效整合了北京大学各平台资源，促进基础研究和临床免疫相结合，为推动临床免疫学科的发展和走向国际发挥重要的作用。

临床免疫中心的主要研究方向将以已有的成果和前期研究为基础，结合目前自身免疫病领域的最新进展，从自身免疫病的发病机制入手，寻找早期诊断的方法，探索新型的免疫干预策略。主要内容如下：

1. 自身免疫病早期诊断靶标和方法的临床及基础研究：重点包括自身免疫病新型的早期诊断生物标记物和标准化平台的建立；规范早期诊断的实验室和影像学方法；建立符合中国特点的自身免疫病诊断标准。

2. 免疫性疾病的发病机制的基础研究：包括揭示自身免疫病分子标记物在发病中的作用；探讨新的细胞亚群在自身免疫病发病机制中的作用。

3. 免疫性疾病新型治疗策略的临床和基础研究：包括蛋白多肽和小分子药物治疗免疫病作用的探讨；靶向抗原特异性T细胞的新策略研究以及自身免疫病干预方案等的研究。

近年来，团队获得的学术及荣誉称号包括：973首席科学家、国家杰出青年基金、国家万人，科技部领军人才，北京大学国华杰出学者奖及吴杨获得者、教育部跨世纪优秀人才、CMB杰出教授、北京市科技新星、教育部新教师基金获得者和青年长江学者等。
   团队成员作为第一或通讯作者在Nature Medicine、Science、Cell H&M、Immunity、Lancet Rheumatology、JAMA Network Open等发表SCI论文500余篇。20余人担任著作/杂志的主编或副主编。主办Rheumatology Autoimmunity杂志，主编或主译了《类风湿关节炎》《凯利风湿病学》等30余部风湿病学专著。在类风湿关节炎诊治及机制研究、系统性红斑狼疮的免疫治疗及干燥综合征的早期诊断方法居国际前列。
   团队成员牵头了973计划、国家自然科学基金重点项目等120余项国家级课题，以及30多项全国多中心研究，推出了类风湿关节炎（RA）的早期分类标准、临床深度缓解标准（CliDR）和抗α胞衬蛋白、膜DNA抗体等一系列诊断标志物；研发了低剂量白介素-2治疗系统性红斑狼疮靶向治疗方法，并用于类风湿关节炎、干燥综合征、肌炎等自身免疫病；研究和推出了RA治疗的持续强化治疗（PRINT）方案，并被国际指南推荐。为推动我国临床免疫专业的国际影响力提升发挥了重要作用。

机构负责人：栗占国

联系人：叶华

邮箱：zgli99@aliyun.com

电话：010-88324173

地址：北京市西城区西直门南大街11号

Clinical Immunology Center of Peking University

Clinical immunology is a rapidly developing and important branch of clinical medicine, which is an essential component of immunology and primarily involves the diagnosis, treatment, and research of various immune diseases.

In 2015, based on the long-term accumulation and development of clinical and basic immunology at Peking University, Professor Zhanguo Li from the People's Hospital led the establishment of the Peking University Clinical Immunology Center, in collaboration with the Rheumatology and Immunology Departments of affiliated hospitals, the Peking University Renal Disease Research Institute, the Basic Immunology Department, and the School of Life Sciences. This effectively integrated resources from various platforms of Peking University, promoted the combination of basic research and clinical immunology, and played an important role in promoting the development and internationalization of clinical immunology.

The main research direction of the Clinical Immunology Center will be based on existing achievements and previous research, combined with the latest progress in the field of autoimmune diseases, starting from the pathogenesis of autoimmune diseases, seeking early diagnostic methods, and exploring new immune intervention strategies. The main contents are as follows: 1. Clinical and basic research on early diagnostic targets and methods for autoimmune diseases. Focusing on the establishment of new early diagnostic biomarkers and standardized platforms for autoimmune diseases; standardizing laboratory and imaging methods for early diagnosis and establishing diagnostic criteria for autoimmune diseases that are in line with Chinese characteristics. 2. Basic research on the pathogenesis of immune diseases, including revealing the role of molecular markers of autoimmune diseases in the pathogenesis and exploring the role of new cell subpopulations in the pathogenesis of autoimmune diseases. 3. Clinical and basic research on novel treatment strategies for immune diseases, including exploration of the therapeutic effects of protein peptides and small molecule drugs on immune diseases and the research on new strategies for targeting antigen-specific T cells and intervention strategies for autoimmune diseases.

In recent years, the team has received academic and honorary titles including: 973 Chief Scientist, National Outstanding Youth Fund, National Ten Thousand Talents, Leading Talent of the Ministry of Science and Technology, Peking University Guohua Outstanding Scholar Award and Wu Yang Award winner, Ministry of Education Cross Century Excellent Talent, CMB Outstanding Professor, Beijing Science and Technology New Star, Ministry of Education New Teacher Fund winner, and Young Changjiang Scholar.

Team members have published over 500 SCI papers as first or corresponding authors in Nature Medicine, Science, Cell H&M, Immunity, Lancet Rheumatology, JAMA Network Open, and others. More than 20 people serve as the chief or deputy chief editors of works/magazines. Hosted the journal of Rheumatology Autoimmunity, edited or translated over 30 rheumatology monographs such as Rheumatoid Arthritis and Kelly Rheumatology. In the diagnosis, treatment, and mechanism research of rheumatoid arthritis, immunotherapy for systemic lupus erythematosus, and early diagnostic methods for Sjogren's syndrome, it ranks among the forefront internationally.

The team members led more than 120 national level projects, including the 973 Program and key projects of the National Natural Science Foundation of China, as well as more than 30 national multicenter studies, and launched early classification criteria and clinical deep remission criteria (CliDR) for rheumatoid arthritis (RA), and a series of diagnostic markers such as anti-a-fodrin and anti-membrane DNA antibodies; We have developed a low-dose interleukin-2 targeted therapy for systemic lupus erythematosus and applied it to autoimmune diseases such as rheumatoid arthritis, Sjogren's syndrome, and myositis; We have studied and launched a continuous intensive treatment (PRINT) regimen for RA treatment, which has been recommended by international guidelines. It has played an important role in promoting the international influence of clinical immunology in China.

Director: Zhanguo Li

Contact: Hua Ye

Email: zgli99@aliyun.com

TEL: 010-88324173

Address: 11 Xizhimen South Street, Xicheng District, Beijing